Published in Science on December 10, 1999
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
Nf1 has an essential role in endothelial cells. Nat Genet (2002) 2.63
Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell (2009) 2.12
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev (2004) 2.04
Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene (2007) 1.97
Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell (2011) 1.96
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 1.95
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86
Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest (2000) 1.72
DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet (2011) 1.65
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol (2012) 1.63
How does the Schwann cell lineage form tumors in NF1? Glia (2008) 1.63
Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. Cancer Cell (2014) 1.57
Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest (2000) 1.56
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A (2004) 1.55
The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell (2008) 1.54
Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell (2005) 1.53
CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell (2013) 1.53
Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep (2012) 1.51
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest (2012) 1.25
Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics (2011) 1.17
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One (2012) 1.13
Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mamm Genome (2009) 1.11
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov (2013) 1.10
Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene (2009) 1.10
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol (2010) 1.09
An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res (2006) 1.08
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest (2006) 1.06
Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res (2011) 1.05
Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum Mol Genet (2010) 1.05
Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget (2014) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep (2013) 1.01
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. Mol Cancer Ther (2010) 1.01
A novel cytokine pathway suppresses glial cell melanogenesis after injury to adult nerve. J Neurosci (2002) 1.00
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res (2012) 0.98
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk. Brain Pathol (2009) 0.97
Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Mol Cell Biol (2003) 0.97
Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell (2012) 0.97
Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma. Am J Pathol (2006) 0.95
Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist (2012) 0.95
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther (2013) 0.95
Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet (2008) 0.94
EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene (2013) 0.94
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. Am J Pathol (2014) 0.93
Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome. Cancer Res (2011) 0.93
Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1. J Clin Pathol (2003) 0.93
Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clin Cancer Res (2015) 0.93
Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics (2007) 0.92
Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics (2010) 0.91
Skin-derived precursors as a source of progenitors for cutaneous nerve regeneration. Stem Cells (2012) 0.91
Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. J Biomol Screen (2008) 0.90
A case of non-Hodgkin's lymphoma in a patient with neurofibromatosis type 1. Korean J Intern Med (2003) 0.90
Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am J Pathol (2013) 0.89
Zebrafish models of p53 functions. Cold Spring Harb Perspect Biol (2010) 0.88
Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol (2009) 0.88
Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech (2012) 0.88
Cis lethal genetic interactions attenuate and alter p53 tumorigenesis. Proc Natl Acad Sci U S A (2010) 0.88
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
The transcriptome that mediates increased cyclic adenosine monophosphate signaling in PRKAR1A defects and other settings. Endocr Pract (2011) 0.88
Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene NFI. Proc Natl Acad Sci U S A (2009) 0.86
Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. Sarcoma (2008) 0.86
Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ (2013) 0.86
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS One (2015) 0.85
Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels. Epigenetics (2007) 0.85
Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol (2008) 0.85
RASopathies: unraveling mechanisms with animal models. Dis Model Mech (2015) 0.84
Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol (2014) 0.84
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A (2013) 0.82
MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene (2014) 0.81
Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res (2013) 0.81
CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget (2016) 0.79
Genome-wide Twist1 occupancy in endocardial cushion cells, embryonic limb buds, and peripheral nerve sheath tumor cells. BMC Genomics (2014) 0.79
MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics (2013) 0.79
Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med (2015) 0.79
Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1. Neurology (2014) 0.78
Recurrent retroperitoneal liposarcoma in a patient with neurofibromatosis type I. BMJ Case Rep (2012) 0.77
Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis. Acta Neuropathol (2014) 0.77
Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors. Neuro Oncol (2015) 0.77
Skin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis. Stem Cells Int (2012) 0.75
Mouse models of inherited cancer syndromes. Hematol Oncol Clin North Am (2010) 0.75
Malignant peripheral nerve sheath tumor of proximal third tibia. World J Clin Oncol (2015) 0.75
Genetics of Bladder Malignant Tumors in Childhood. Curr Genomics (2016) 0.75
EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation. Oncogene (2016) 0.75
Disease models and mechanisms in the classroom. Dis Model Mech (2009) 0.75
Phylooncogenomics: Examining the cancer genome in the context of vertebrate evolution. Appl Transl Genom (2013) 0.75
Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget (2016) 0.75
An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors. EBioMedicine (2016) 0.75
Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma (2017) 0.75
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol (2016) 0.75
Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem (2017) 0.75
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA (1997) 8.30
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (1998) 5.40
The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell (1999) 4.54
Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell (1992) 4.26
A genetic linkage map of the mouse: current applications and future prospects. Science (1993) 4.24
The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell (1990) 4.12
Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet (1994) 3.97
Smad3 mutant mice develop metastatic colorectal cancer. Cell (1998) 3.92
Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40
Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev (1994) 3.40
Alternative neural crest cell fates are instructively promoted by TGFbeta superfamily members. Cell (1996) 3.39
Tumor spectrum in ARF-deficient mice. Cancer Res (1999) 3.11
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52
Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet (1998) 2.32
Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature (1990) 2.28
Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet (1993) 2.10
p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol (1996) 1.67
Tumor suppressor genes. Curr Opin Genet Dev (1994) 1.57
Tumor suppressor gene mutations in mice. Annu Rev Genet (1996) 1.42
Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev (1999) 1.37
Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer (1992) 1.29
Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene (1996) 1.18
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol (1997) 1.17
Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet (1994) 1.08
Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol (1994) 1.03
Leiomyosarcoma of the small intestine associated with von Recklinghausen's disease: report of a case. Surgery (1992) 0.93
Neurofibromatosis and related tumors. Natural occurrence and animal models. Am J Pathol (1994) 0.86
Sympathetic neuron survival and proliferation are prolonged by loss of p53 and neurofibromin. Mol Cell Neurosci (1998) 0.85
Involvement of the Ink4a gene (p16 and p19arf) in murine tumorigenesis. Int J Oncol (1999) 0.85
Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Cold Spring Harb Symp Quant Biol (1994) 0.82
Making of a Schwann. Trends Genet (1996) 0.82
Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Digestion (1999) 0.81
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (1983) 19.76
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Cellular oncogenes and multistep carcinogenesis. Science (1983) 6.52
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev (2001) 4.68
High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature (1991) 4.44
Smad3 mutant mice develop metastatic colorectal cancer. Cell (1998) 3.92
The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science (1991) 3.86
Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (1995) 3.55
BDNF regulates eating behavior and locomotor activity in mice. EMBO J (2000) 3.52
Analysis of Hox gene expression in the chick limb bud. Development (1996) 3.47
Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev (1994) 3.40
Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature (1991) 3.37
The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell (1990) 3.21
The HL-60 transforming sequence: a ras oncogene coexisting with altered myc genes in hematopoietic tumors. Cell (1983) 3.00
Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol (1986) 2.86
Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev (1992) 2.54
The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell (1991) 2.46
Supplemental social services improve outcomes in public addiction treatment. Addiction (1998) 2.21
Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature (1986) 2.15
trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J (1989) 2.14
Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol (1992) 2.07
Images in clinical medicine. Schistosoma haematobium. N Engl J Med (2000) 2.04
K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J Biol Chem (1992) 2.01
Cryptorchidism in mice mutant for Insl3. Nat Genet (1999) 1.99
Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene (2007) 1.97
Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation. Neuron (1992) 1.96
Expression of the tyrosine kinase receptor gene trkB is confined to the murine embryonic and adult nervous system. Development (1990) 1.75
Absence of sensory neurons before target innervation in brain-derived neurotrophic factor-, neurotrophin 3-, and TrkC-deficient embryonic mice. J Neurosci (1997) 1.70
Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev (1990) 1.67
Forward signaling mediated by ephrin-B3 prevents contralateral corticospinal axons from recrossing the spinal cord midline. Neuron (2001) 1.64
Targeted deletion of all isoforms of the trkC gene suggests the use of alternate receptors by its ligand neurotrophin-3 in neuronal development and implicates trkC in normal cardiogenesis. Proc Natl Acad Sci U S A (1997) 1.62
The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells. Neuron (1993) 1.61
Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. Proc Natl Acad Sci U S A (2000) 1.60
Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol Cell Biol (2001) 1.58
Targeted mutation in the neurotrophin-3 gene results in loss of muscle sensory neurons. Proc Natl Acad Sci U S A (1994) 1.54
Brain remodeling due to neuronal and astrocytic proliferation after controlled cortical injury in mice. J Neurosci Res (2001) 1.53
Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-gamma 1 by a kinase activity associated with the product of the trk protooncogene. Proc Natl Acad Sci U S A (1991) 1.53
Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res (2001) 1.53
Radiologic-pathologic correlation: hemangioblastoma. AJNR Am J Neuroradiol (1992) 1.50
Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes. J Virol (1994) 1.50
The trk proto-oncogene rescues NGF responsiveness in mutant NGF-nonresponsive PC12 cell lines. Cell (1991) 1.47
trkC, a receptor for neurotrophin-3, is widely expressed in the developing nervous system and in non-neuronal tissues. Development (1993) 1.46
Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol (2006) 1.43
Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene (1999) 1.41
Optic pathway glioma infiltrating into somatostatinergic pathways in a young boy with gigantism. Case report. J Neurosurg (1994) 1.40
Does clinical case management improve outpatient addiction treatment. Drug Alcohol Depend (1999) 1.39
Rosenthal fibers and eosinophilic granular bodies in a classic acoustic schwannoma. Arch Pathol Lab Med (1997) 1.39
N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum (1994) 1.39
Bad news and good news: what the dentist needs to know about transmissible spongiform encephalopathies. Quintessence Int (1998) 1.38
Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. Development (1993) 1.38
p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron (1992) 1.38
Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J (1991) 1.37
p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J Neurosci (1998) 1.34
Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials. AIDS Educ Prev (1997) 1.26
In vivo role of truncated trkb receptors during sensory ganglion neurogenesis. Neuroscience (2003) 1.20
Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell (1995) 1.20
Presence of a Kirsten murine sarcoma virus ras oncogene in cells transformed by 3-methylcholanthrene. Mol Cell Biol (1983) 1.18
Hormones in male sexual development. Genes Dev (2000) 1.18
Trks: signal transduction and intracellular pathways. Microsc Res Tech (1999) 1.14
An immunoglobulin-like domain determines the specificity of neurotrophin receptors. EMBO J (1995) 1.13
Regulation of neurotrophin receptor expression during embryonic and postnatal development. J Neurosci (1994) 1.12
Induction by NGF of meiotic maturation of Xenopus oocytes expressing the trk proto-oncogene product. Science (1991) 1.11
A molecular basis for estrogen-induced cryptorchidism. Dev Biol (2000) 1.11
The binding epitopes of neurotrophin-3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin. EMBO J (1994) 1.11
Loss of brain-derived neurotrophic factor-dependent neural crest-derived sensory neurons in neurotrophin-4 mutant mice. Proc Natl Acad Sci U S A (2000) 1.10
NT4/5 mutant mice have deficiency in gustatory papillae and taste bud formation. Dev Biol (1999) 1.09
The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A (1997) 1.09
Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression. Oncogene (2006) 1.07
Role of N-myc in the developing mouse kidney. Dev Biol (2000) 1.05
Germ line transmission of an inactive N-myc allele generated by homologous recombination in mouse embryonic stem cells. Mol Cell Biol (1990) 1.04
Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene (2012) 1.03
Potential role of glial cell line-derived neurotrophic factor receptors in Müller glial cells during light-induced retinal degeneration. Neuroscience (2003) 1.01
In vivo and in vitro infection of the astrocyte by HIV-1. Adv Neuroimmunol (1994) 1.01
A muscle disorder of Labrador retrievers characterized by deficiency of type II muscle fibers. J Am Vet Med Assoc (1976) 1.00
TrkC isoforms with inserts in the kinase domain show impaired signaling responses. J Biol Chem (1996) 0.98
Congenital ependymoblastoma arising in the sacrococcygeal soft tissue: a case study. Clin Neuropathol (2008) 0.98
Mice lacking NT-3, and its receptor TrkC, exhibit profound deficiencies in CNS glial cells. Glia (1999) 0.97
Regulation of Trk receptors following contusion of the rat spinal cord. Exp Neurol (2001) 0.97
Molecular characterization of the TrkA/NGF receptor minimal enhancer reveals regulation by multiple cis elements to drive embryonic neuron expression. Development (2000) 0.97
The relationship of Axis II personality disorders to other known predictors of addiction treatment outcome. Am J Addict (1999) 0.95
Insulin receptor-related receptor expression in non-A intercalated cells in the kidney. Kidney Int (1997) 0.95
Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. J Rheumatol (1995) 0.95
Neurotrophins are not required for normal embryonic development of olfactory neurons. Dev Biol (2001) 0.95
The Ras-ERK pathway is required for the induction of neuronal nitric oxide synthase in differentiating PC12 cells. J Neurochem (2001) 0.95
Neurotrophin-3 induced by tri-iodothyronine in cerebellar granule cells promotes Purkinje cell differentiation. J Cell Biol (1993) 0.95
High throughput method for creating and screening recombinant adenoviruses. Gene Ther (1998) 0.94
Formation of the arterial media during vascular development. Cell Mol Biol Res (1995) 0.94
Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. Cold Spring Harb Symp Quant Biol (2008) 0.93
mKlf7, a potential transcriptional regulator of TrkA nerve growth factor receptor expression in sensory and sympathetic neurons. Development (2001) 0.93
c-ros: the vertebrate homolog of the sevenless tyrosine kinase receptor is tightly regulated during organogenesis in mouse embryonic development. Development (1992) 0.92
Distribution of trkB tyrosine kinase immunoreactivity in the rat central nervous system. Brain Res (1993) 0.91
In situ hybridization. Methods Enzymol (1995) 0.91
Receptor tyrosine kinase signaling in vascular development. Cell Growth Differ (1997) 0.91
Altered regulation of brain-derived neurotrophic factor protein in hippocampus following slice preparation. Neuroscience (2004) 0.90
Transcriptional regulation of Trk family neurotrophin receptors. Cell Mol Life Sci (2007) 0.90
"Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. J Addict Dis (1997) 0.90